Ifosfamide is a well known prodrug for cancer treatment with cytochrome P450 metabolism. It is associated with both antitumor activity and toxicities. Isophosphoramide mustard is the bisalkylating active metabolite, and acrolein is a urotoxic side product. Because acrolein toxicity is limited by coadministration of sodium mercaptoethanesulfonate, the incidence of urotoxicity has been lowered. Current evidence suggests that chloroacetaldehyde, a side-chain oxidation metabolite, is responsible for neurotoxicity and nephrotoxicity. The aim of our research is to prevent chloroacetaldehyde formation using new enantioselectively synthesized ifosfamide analogs, i.e., C7,C9-dimethyl-ifosfamide. We hypothesize that reduced toxicogenic catabolism may induce less toxicity without changing anticancer activity. Metabolite determinations of the dimethyl-ifosfamide analogs were performed using liquid chromatography and tandem mass spectrometry after in vitro biotransformation by drug-induced rat liver microsomes and human microsomes expressing the main CYP3A4 and minor CYP2B6 enzymes. Both human and rat microsomes incubations produced the same N-deschloroalkylated and 4-hydroxylated metabolites. A coculture assay of 9L rat glioblastoma cells and rat microsomes was performed to evaluate their cytotoxicity. Finally, a mechanistic study using 31 P NMR kinetics allowed estimating the alkylating activity of the modified mustards. The results showed that C7,C9-dimethyl-ifosfamide exhibited increased activities, although they were still metabolized through the same N-deschloroalkylation pathway. Analogs were 4 to 6 times more cytotoxic than ifosfamide on 9L cells, and the generated dimethylated mustards were 28 times faster alkylating agents than ifosfamide mustards. Among these new ifosfamide analogs, the 7S,9R-enantiomer will be assessed for further in vivo investigations for its anticancer activity and its toxicological profile.
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The bisalkylating agent ifosfamide (IFO) was introduced into clinical trials in the 1970s, but its early use was limited by severe urotoxicity resulting in hemorrhagic cystitis. This side effect led to the development of sodium mercaptoethanesulfonate associated with hydration as a safe and effective regional uroprotection. Further studies have demonstrated IFO activity against a wide range of tumor types, from soft tissue sarcomas to lymphomas both in adult and pediatric patients (Kerbusch et al., 2001) . Main adverse effects of IFO include urotoxicity, myelosuppression, nausea and vomiting, neurotoxicity, and nephrotoxicity. Le Cesne et al. (1995) have shown that high-dose regimen of IFO allowed the circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas, indicating that there is a dose-effect relationship. Since the systematic use of adjuvant treatments such as sodium mercaptoethanesulfonate, granulocyte-macrophage colony-stimulating factor, and setrons, and the increase of IFO dosages, neurotoxicity and nephrotoxicity are the limiting factors for IFO-based chemotherapy (Aleksa et al., 2001; Lee et al., 2001 ). Indeed, in some studies, up to 40% of the treated patients show neurological disorders depending on the dose quantity and the administration mode, and another 5% present a Fanconi syndrome (Patzer et al., 2006) . These toxicities seem to be more frequent in children (Dufour et al., 2006) .
Ifosfamide (1) is a prodrug with metabolism being required to obtain its active form. The initial activation reaction in IFO metabolism is mainly mediated by the cytochrome P450 (P450) enzyme CYP3A4 (Fig. 1) . Hydroxylation on the C4 of the oxazaphosphorine ring leads to 4-hydroxy-ifosfamide (4-OH-IFO, 2), which is in equilibrium with its tautomeric form, the aldo-ifosfamide (3). The latter may then either be oxidized by aldehyde dehydrogenase 1 to carboxyl-ifosfamide (4), an inactive metabolite, or spontaneously to acrolein (5), by a retro-Michael reaction, and the isophosphoramide mustard (IPM, 6), which is the active moiety. IPM is the bisalkylating moiety, and acrolein is believed to be responsible for urotoxicity. Up to 50% of an IFO dose undergoes enzymatic oxidative N-dealkylation, resulting in the loss of chloroethyl side chains and producing
). An equimolar amount of chloroacetaldehyde (CAA, 10) is formed in each of these N-dealkylation reactions. This metabolite is known to be responsible for both nephrotoxicity and neurotoxicity, which may be associated with IFO treatment (Boddy and Yule, 2000; Chatton et al., 2001; Ajithkumar et al., 2007) , even if it has been recently reported that CAA could contribute to IFO cytotoxicity (Brü ggemann et al., 2006) . Reducing CAA formation may reduce frequency of IFO-related neurotoxicity and nephrotoxicity.
To prevent CAA toxicities, different strategies have been proposed. First, Kü pfer et al. (1996) relieved patients from neurotoxicity using methylene blue to decrease CAA toxicity. Visarius et al. (1999) demonstrated the pharmacological mechanism of methylene blue use. Unfortunately, methylene blue is not conveniently used in prophylaxis but is mainly limited to relieve symptoms.
Second, because some P450 isoforms are more implicated in IFO N-deschloroethylation, specific isoform inhibition in the toxicogenic pathway should prevent CAA formation (Scripture et al., 2005) . Nevertheless, this approach is not compatible with clinical use. Indeed, cancer patients receive several drugs that are mainly metabolized by P450 enzymes in the liver. The benefit associated with blockage of CAA formation from IFO may be largely overshadowed by increased toxicity of associated treatments.
The third option we developed involved the synthesis of new IFO analogs C7,C9-dimethyl-ifosfamide (C7,C9-diMe-IFO, 11) ( Fig. 1) , designed to lower the susceptibility of side-chain oxidation through methylation of the C7-and C9-positions. First, the steric hindrance created should decrease enzymatic access. Second, the methyl group electron-donor effect reduces oxidability. Finally, even if the extracyclic oxidation occurs, the side product will be chloroacetone and not CAA. From a chemical point of view, ␣-halogeno methylketones are less reactive than their aldehyde homologs.
Two C7,C9-diMe-IFO analogs [7S,9R-dimethyl-ifosfamide (TS121) and 7S,9S-dimethyl-ifosfamide (TS125)] were chosen for the pharmacological study on the basis of their easy access from the natural isomer of alanine. Their evaluation results are presented. Because side chains were modified from IFO, it was mandatory to investigate the N-deschloroalkylation metabolism, the cytotoxic activity, and the alkylation potential of these newly synthesized analogs.
Materials and Methods

Chemicals and Reagents
Ifosfamide [Holoxan; 2-(2-chloroethylamino)-3-(2-chloroethyl) tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide] and cyclophosphamide [Endoxan; amino] tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide] were obtained from Baxter SA (Maurepas, France) . N 2 -DCE-IFO, N 3 -DCE-IFO, C7,C9-diMe-IFO analogs (TS121 and TS125), and their desalkylated metabolites were enantioselectively synthesized according to previously developed techniques (Paci et al., 2001) . Their purity and chemical structures were assessed by 31 P, 13 C, 1 H NMR study and electrospray ionization (ESI)-mass spectrometry. HPLC grade solvents (methanol and ethyl acetate) and ammonium formate were obtained from Carlo Erba (Rodano, Italy). Sodium thiosulfate pentahydrate (Na 2 S 2 O 3 ⅐5 H 2 O; Ͼ99.5% purity) and magnesium chloride were obtained from Acros Organics (Geel, Belgium). Deionized water was prepared using a UHQ II system (USF ELGA S.A., Trappes, France). Phenobarbital, polychlorinated biphenyl (Aroclor 1254), NADP, NADPH, glucose 6-phosphate, glucose-6-phosphate dehydrogenase, and 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) stain were provided by Sigma-Aldrich (St. Louis, MO). Culture reagents [DMEM, concentrated penicillin/streptomycin antibiotic mixture, fetal bovine serum (FBS), and trypsin-EDTA] were purchased from Gibco (Paisley, UK).
Metabolic Investigations
Preparation of Rat Liver Microsomes. Procedures involving animals were carried out in compliance with the conditions established by the European Union (directives 86/609/CE and 2003/65/ CE). Livers were obtained from noninduced Sprague-Dawley male rats or from male rats treated with 500 mg/kg polychlorinated biphenyl once daily for 3 days or with 80 mg/kg phenobarbital once daily for 3 days. Microsomes were prepared as described previously (Abernathy et al., 1971) .
Human Microsomes Expressing P450 Enzymes. Three batches HG42 (452042), HG112 (452112), and HH74 (452174) human microsomes expressing mainly CYP3A4 and CYP2B6, provided by BD Gentest (Woburn, MA), were used for IFO and diMe-IFO analog incubations.
Microsomal Incubations. A typical incubation sample contained 1 mg of rat or human liver microsomal proteins, 0.1 M potassium phosphate buffer, pH 7.4, 5 mM magnesium chloride, 40 mM glucose 6-phosphate, 2 mM NADP, and 20 IU of glucose-6-phosphate dehydrogenase in a final volume of 0.5 ml (Storme et al., 2005) . Samples were preincubated for 10 min at 37°C. Afterward, 1 mol of the compound (IFO or C7,C9-diMe-IFO) was added to give a final concentration of 2 mM. Incubations were carried for 0.5 or 1 h for rat and human microsomes and stopped by adding 5.0 ml of ice-cold ethyl acetate. After centrifugation at 6000g, the organic layer was decanted and evaporated to dryness under nitrogen. The residue was stored at Ϫ20°C until analysis. It was then dissolved in methanol and diluted 5-fold in the 5 mM ammonium formate solution, and a 20-l aliquot was analyzed by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS).
HPLC-MS/MS
Microbore HPLC. The HPLC-MS/MS method was adapted from a previously described technique (Storme et al., 2005) . Sample extracts and IFO standards were analyzed with a 1100 series HPLC system (Agilent Technologies, Massy, France), including a binary pump, a bypass loop autosampler, and a NucleosilC18HD 5-m column (1 mm i.d. ϫ 150 mm in length; Interchim, Montluçon, France). Gradient elution was performed at a flow rate of 60 l/min, with eluent A (5 mM ammonium formate, pH 5.5/methanol) (80:20, v/v) and eluent B (5 mM ammonium formate, pH 5.5/methanol) (20:80, v/v) . IFO and its metabolites were analyzed with the following gradient method: starting with 100% eluent A, the gradient mixture was increased up to A/B (50:50, v/v) from 5.0 to 6.0 min and was kept until 15.0 min, then back again to initial conditions for 10.0 min. C7,C9-diMe-IFO (TS) and their metabolites were analyzed with the following gradient method: starting with 100% eluent A, the gradient mixture was increased up to A/B (20:80, v/v) from 5.0 to 6.0 min and was kept for 9.0 min and then back again to initial conditions until 30.0 min. 
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Electrospray Mass Spectrometry. Detection was performed with a Quattro-LCZ triple-quadrupole mass spectrometer equipped with an orthogonal electrospray source (Micromass, Manchester, UK). The ESI source and nitrogen gas temperatures were set at 90 and 200°C, respectively. The ESI voltage and the cone voltage were set at 3500 and 30 V, respectively. Product ion scan mode was used with collision-induced dissociation. The collision energy was set at 20 eV, with argon in the collision cell. Continuous positive ion electrospray spectra were obtained over the scan range m/z 50 to 300 in 0.5 s using the Masslynx software (Micromass).
Cytotoxic Activity on 9L Cells
9L Cells. The rat gliosarcoma cell line 9L is a brain tumor-derived adherent cell line and was cultured in DMEM supplemented with sodium hydrogen carbonate (3.7 g/l), with 1% dilution of concentrated penicillin/streptomycin antibiotic mixture and with 2% FBS. Cells were cultured at 37°C in a humidified incubator containing 5% CO 2 atmosphere. Cells were grown in 25-cm 2 tissue culture flask (Cellstar; Greiner Bio-One, Frickenhausen, Germany) filled with 5 ml of culture medium.
Microsome-Prodrug Coculture Assay. As described previously by Baldwin et al. (2003) , the 9L cells were seeded in 96-well tissue culture microplates (Cellstar; Greiner Bio-One) at a density of 1000 cells/100 l/well and allowed to attach for 24 h. The top row of each plate remained empty as a cell-free staining negative control. The same culture media were used as described above except for FBS concentration, increased to 10%. For cytotoxicity investigations of the prodrug at different concentrations, NADPH (final concentration, 1.5 mM) and 1 g of rat liver microsomes were added to each well (final volume, 100 l). Increasing concentrations of prodrug from 0 to 0.3 M diluted in culture media were then added to each well. For cytotoxic investigations according microsomes concentration, NADPH (final concentration, 1.5 mM) and prodrugs at IC 50 concentration were added to each well (final volume, 100 l). Increasing amounts of microsomal proteins from 0 to 4 g diluted in culture media were then added to each well. The top two rows were used as blank row and negative control (no prodrug/microsome). Each prodrug/microsomes concentration combination was assayed in triplicate. After 6 h, 100 l of culture media was added for routine culture over 4 days after the addition of prodrug. Cells were stained according to the MTT assay adapted from Mosmann (1983) . After incubation for 2 h at 37°C with 100 l of a 10% (w/v) MTT solution in culture media, the plate was then gently shaken, and 100 l of a lysis solution (200 g of SDS in 1 l of dimethyl formamide/H 2 O, 1:1, v/v, pH 4.7) was added into each well. After 1 h of shaking at room temperature, the plates were read on a Multiscan 355 (Thermo Electron, Courtaboeuf, France) using a test wavelength of 570 nm and a reference wavelength of 630 nm.
As described by Baldwin et al. (2003) , data are expressed in individual figures as relative growth rate at each drug concentration (with error bars representing S.D.), determined by dividing the absorbance value for a given prodrug concentration by the absorbance of the drug-free control. A value of 1 corresponds to 100% cell growth rate, relative to the drug-free control. Trends presented in each figure are representative of two or three independent experiments; graphs shown and IC 50 values mentioned in the text are based on single experiments deemed most representative. Pictures of cell culture wells were achieved using an Axiovert 135 (Carl Zeiss, Jena, Germany) fluorescence microscope.
P NMR Kinetic Study of Mustard Alkylating Activity
NMR experiments were performed on a BRUKER AVANCE-400 NMR spectrometer (Bruker, Wissembourg, France). The 31 P NMR kinetic technique and mustard syntheses were adapted from Boal et al. (1989) and Springer et al. (2004) .
31 P NMR Kinetic Studies: General Procedure. NMR sample solutions of IPM and its dimethylated analog (diMe-IPM) were prepared immediately before their use by adding buffer containing the trapping agent to a glass flask, which contained the compound of interest (usually around 30 mg in 1 ml of buffer). This latter consisted in 0.1 M sodium phosphate buffer, pH 7.4, where a trapping agent in excess (5 M equivalents at least), e.g., sodium thiosulfate, pentahydrate was added before dissolution of IPM or diMe-IPM. The buffer contained 10% (v/v) deuterium oxide to facilitate NMR experiments. The pH of the resultant solution was adjusted to 7.4 as necessary (1 M HCl or NaOH), and the solution was transferred to a 5-mm NMR tube. Only kinetic runs presenting variations of less than 0.5 pH units were included for the analysis. When experiments were not performed at room temperature, the sample was allowed to thermally equilibrate for several minutes before data collection.
At the same time, magnetic field homogeneity was made on a blank NMR tube filled with buffer plus trapping agent. A glass insert containing 25% aqueous H 3 PO 4 was added to the blank NMR tube to be used as a chemical shift standard. The sample was then placed in the NMR probe, and a final adjustment of the magnetic field homogeneity was performed before the initiation of spectral acquisition. For the first kinetic analysis of a compound, the spectra were obtained every 10 to 20 min. In repeated kinetic analyses, the spectra were obtained at time intervals appropriate to the reactivity of the compound as indicated by the initial experiment.
31 P NMR acquisitions at 162.0 MHz used a 3200-Hz spectral window, 4000 data points, a one-dimensional sequence with 1 H broad-band decoupling using WALTZ16 decoupling program (Shaka et al., 1983) . Each experiment consisted of 200 scans lasting 2 min 33 s, unless otherwise indicated.
The free induction decay signal was automatically stored, and the next spectral acquisition was initiated at time t, relative to the "zero" time (initiation of first acquisition). The stored free induction decay signals were exponentially multiplied so as to result in an additional 1 Hz of line broadening in the frequency-domain spectra.
For the diMe-IPM alkylation kinetics, the accumulation time (2 min 33 s) was too long compared with the speed of transformation to obtain meaningful results. Thus, acquisition parameters were modified to shorten each NMR experimental duration and to maintain adequate resolution, i.e., a spectral window of 2260 Hz, 2000 data points, and 64 scans. Moreover, the line broadening in the frequencydomain spectra was modified to 0.3 Hz. These modifications allowed good sensitivity in for an acquisition period of 40 s. This was compatible with the faster transformation kinetics reported for diMe-IPM.
NMR data were analyzed as the sum of integrals normalized to 100%. Peak areas were used to measure the relative proportions of the corresponding compounds. Kinetic progress curves (proportions versus time) were analyzed using the nonlinear squares fitting program DynaFit, with the following kinetic diagram (Kuzmic, 1996) : ANBNC.
Results
Biotransformation of IFO and Its Analogs
Dealkylated IFO metabolites are the best markers of IFO neurotoxicity. According to Yu and Waxman (1996) , rat liver cytochrome P450 2B leads to IFO N-deschloroethylation. Because phenobarbital is a strong inducer of these P450 2Bs, metabolism experiments were performed using phenobarbital-or polychlorinated biphenyl-induced rat microsomes and compared with noninduced rat microsomes, both in the presence of NADPH.
The HPLC-MS/MS analyses of IFO incubations ( Fig. 2A ) were performed to identify IFO metabolites by means of their mass spectra and to evaluate the metabolism yield of the prodrug into N-deschloroethylated metabolites (toxic pathway) and into 4-hydroxylated metabolite (active pathway). ϩ -CHϭCH-Cl (m/z 92) with a difference of 14 mass units, corresponding to a methyl group, confirming fragments ions described previously for IFO, whose interpretation was facilitated by various deuterated IFO analogs (Liu et al., 2005) . 
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Induced and noninduced rat microsomes were incubated over 1 h, instead of 0.5 h, to detect significant amounts of active metabolites of IFO and IFO analogs (4-OH-IFO and 4-OH-diMe-IFO) (data not shown). Phenobarbital-induced rat microsomal incubations (n ϭ 3) of 2 mM IFO and of C7,C9-diMe-IFO (TS121 and TS125) induced the following three metabolites after 1-h incubation time (summarized in Table 1 ). For IFO metabolism, yields were 1.2% for N 2 -DCE-IFO, 5.2% for N 3 -DCE-IFO, and 10.0% for 4-OH-IFO. For the metabolism of the 7S,9R-analog (TS121), yields were 12.5% for N 2 -DCP-Me-IFO, 22.3% for N 3 -DCP-Me-IFO, and 6.0% for 4-OH-diMe-IFO. For the 7S,9S-analog (TS125), yields were 29.5% for N 2 -DCP-Me-IFO, 22.8% for N 3 -DCP-Me-IFO, and 3.0% for 4-OH-diMe-IFO. Because 83.6% IFO remained unchanged, 59.1% C7,C9-diMe-IFO (TS121) and 44.7% C7,C9-diMe-IFO (TS125) were not metabolized using phenobarbital-induced rat microsomes.
Because polychlorinated biphenyl is a strong inducer of a wide range of cytochrome P450 isoforms (1A, 2B, and 3A) of the total oxidase activity (Ryan and Levin, 1990) , metabolism experiments were first performed using polychlorinated biphenyl-induced rat microsomes (n ϭ 3). As shown in Table 1 , whereas 92.1% IFO remained unchanged, 70.0% TS125 and 75.5% TS121 were metabolized using polychlorinated biphenyl-induced rat microsomes with 25% of its of activated metabolite, 4-hydroxy-diMe-IFO, versus 5.2% for 4-hydroxy-IFO. The latter results with activated metabolites may be interesting for cytotoxic activity; however the values should be interpreted with caution because 4-hydroxy-compounds are strongly labile.
The IFO incubation time was set at 1 h rather than 0.5 h with human microsomes expressing CYP3A4 and CYP2B6 to produce the 4-hydroxy-IFO active metabolite in sufficient yields and the two N-DCE-IFO metabolites. For both IFO analogs, the N-DCP-methyl-IFO and the 4-hydroxy-diMe-IFO metabolites were detected by liquid chromatography-MS/MS either after 0.5 or 1 h of incubation. Relative estimation of biotransformation is shown for 1 h in Table 2 . The biotransformation rates, however, were very low. Human microsomal incubations of TS121 (7S,9R-) and TS125 (7S,9S)-dimethylated IFO analogs produced the same hydroxylated metabolite and the two N-DCP-methyl-IFO metabolites observed after rat microsomes incubations, thus confirming the same metabolism pathway. Moreover, the metabolism rates seemed to be faster for analogs compared with IFO as observed with the rat microsomes. The hydroxylated metabolites were produced more readily for TS121 and TS125, but side chain oxidations also generated metabolites.
Cytotoxic Activity on 9L Cells
9L Cells Growth Inhibition Assay. Evaluation of oxazaphosphorine prodrugs cytotoxicity, thanks to microsomal cytochrome P450 using 9L rat gliosarcoma cells, was first described by Baldwin et al. (2003) . In fact, their experiments demonstrated that an extracellular source of P450 activity, such as liver microsomes extract, can enhance P450 prodrug cytotoxicity in a manner comparable with that obtained using P450-expressing tumor cell lines (Baldwin et al., 2003) .
After a preliminary study, the number of cells per well (450 versus 1000 cells/well), the culture media (DMEM supplemented with 2% versus 10% FBS), and the growth time (3, 4, 5, 6, or 7 days) were slightly adapted. The retained conditions (1000 cells/well in DMEM supplemented with 10% FBS and pyruvate, after 5 days of growth) allowed the production of sufficient active metabolites according to the number of cells per plate for the MTT assay.
Microsome-prodrug coculture assays were designed such that each well contained NADPH, prodrug, and liver microsomes isolated from either noninduced or drug-induced rats. Microsomes isolated from drug-induced rat liver were first tested for their ability to activate the CPM and IFO prodrugs. After a 4-day period of cell incubation with the prodrug and liver microsomes, the cells were stained according to the MTT method, and the relative cell growths were determined following subtraction of background staining (microsomal protein in the absence of cells).
The IC 50 values obtained for IFO and CPM (0.500 and 0.150 mM) were consistent with previously described results (Baldwin et al., 2003) . For IFO analogs (TS125 and TS121), IC 50 values were first calculated at 0.130 and 0.080 mM, respectively, and were consistent with a higher cytotoxicity, which can be due to a higher activation rate or to a higher intrinsic cytotoxicity of the diMe-IPM, or a combination.
As shown in Fig. 3 , top, no significant cytotoxicity was observed for IFO and for IFO analogs in the absence of microsomes. As the drug concentration increased, cell viability decreased to 75% after 4 days, with a prodrug concentration of 0.3 mM and 1 g of microsomes protein for IFO but decreased to 25% for TS121 and TS125.
In accordance with increased drug concentrations, the IC 50 results and cell viability prompted comparison of IFO and CPM analogs with noninduced and phenobarbital-induced microsomes. Figure 3 , middle, indicates cell cultures with rat phenobarbital-induced microsomes at the concentration used with the determined concentration of prodrugs (0.5 mM for IFO and CPM, and 0.15 mM for dimethyl analogs) showed significant differences between analogs and oxazaphospho- for TS125, respectively). The two tested analogs were more cytotoxic than CPM (32%) and also IFO (66%). Figure 3 , bottom, indicates that the noninduced microsome concentration used with the same prodrug concentration (0.5 mM for IFO and CPM and 0.15 mM for dimethyl analogs) gave significant differences between analogs and IFO. These experiments demonstrated that they were 4-to 6-fold more cytotoxic than ifosfamide on 9L gliosarcoma cells. TS121 and TS125 were much more cytotoxic than clinically available oxazaphosphorine drugs; 48 and 52% of cell viability at 2 g of microsomes protein for TS121 and TS125, respectively, and 68 and 71% for IFO and CPM. The results can be readily observed as microscopic views depicted on Fig. 4 . All compounds were activated giving cytotoxic moieties in the presence of microsomes, whereas no significant cytotoxicity was confirmed in the absence of microsomes for IFO, CPM, and C7,C9-diMe-IFO compounds, permitting their description as prodrugs.
P MNR Kinetic Study of Mustard Alkylating Activity
The alkylating activity of diMe-IPM was compared with IPM to check that IFO analogs produce an effective mustard that could help explain the observed cytotoxicity. To obtain a kinetic reference, the previously described 31 P NMR kinetic measurements with IPM in the presence of excess sodium thiosulfate (used as trapping nucleophilic agent) were reproduced in the NMR instrument.
Our experiments were adapted from Boal et al. (1989) and from Springer et al. (1998) . As seen in Fig. 5A , the gradual disappearance of the 31 P NMR signal for IPM-Cl 2 occurred alongside the steady growth of a new signal (labeled as IPMAlk 2 ), assigned to the anticipated and previously described bisalkylation product. A signal was also observed for a transient species (labeled as the monoalkylated intermediate IPM-Alk/Cl), kinetically associated with the two other species. This signal has been assigned previously to IPM-Alk/Cl (Fig. 5A) (Springer et al., 1998) . It has been shown that in the reaction sequence IPM-Cl 2 3 IPM-Cl/Alk 3 IPM-Alk 2 , the formation of both IPM-Alk/Cl and IPM-Alk 2 was preceded by an intramolecular cyclization of the chloroethylamido functionality, resulting in the formation of an aziridine. In the presence of an excess of nucleophiles, such as thiosulfate, the electrophilic aziridine was short lived, and this sequence (IPM-Cl 2 3 IPM-ClAlk 3 IPM-Alk 2 ) can be treated kinetically as two simple, consecutive "first-order" reactions. Because there was an excess of nucleophile, its concentration can be considered as a constant and included in the k exp : IPM-Cl 2 3 IPM-Cl/Alk: k exp1 ; and IPM-Cl/Alk 3 IPM-Alk 2 : k exp2 . k exp1 represents either the disappearance rate of IPM-Cl 2 (independently of the presence of intermediates between IPM-Cl 2 and IPM-Alk/Cl), or the composite production rate of IPM-Cl/Alk from IPM-Cl 2 ; similarly, for k exp2 and IPMAlk/Cl and IPM-Alk 2 . Because intermediate species were not observed in the presence of trapping agents, their conversion rates to IPM-Alk/Cl and IPM-Alk 2 must be fast, and thus, the composite rate closely approximates to the conversion rate of the observed species. The proportions of the different forms as a function of time is depicted (Fig. 6) . The k exp1 and k exp2 rates were fitted to the observed proportions of the different forms applying classical first-order kinetic equations.
Least-squares fitting of the 31 P NMR data (signal relative intensities of IPM-Cl 2 , IPM-Cl/Alk, and IPM-Alk 2 ) resulted in values of k exp1 and k exp2 of 11.636 ϫ 10 Ϫ3 min Ϫ1 Ϯ 0.79% and 6.119 ϫ 10 Ϫ3 min Ϫ1 Ϯ 0.71%, respectively, at 37°C, consistent with previously obtained results (Boal et al., 1989) . Rate constants for dime-IPM were determined under similar reaction conditions. At 37°C, alkylation is so fast that there is no associated result (data not shown). Thus, diMe-IPM kinetic has been performed at room temperature (20°C). It was found that k exp1 ϭ 34.184 ϫ 10 Ϫ3 min Ϫ1 Ϯ 1% and k exp2 ϭ 16.170 ϫ 10 Ϫ3 min Ϫ1 Ϯ 1.4% for the diMe-IPM at room temperature. IPM transformation kinetics experiments were performed at room temperature for comparison. As expected, the kinetics was much slower, borne out by the rate constants: k exp1 ϭ 1.129 ϫ 10 Ϫ3 min Ϫ1 Ϯ 0.64% and k exp2 ϭ 0.602 ϫ 10 Ϫ3 min Ϫ1 Ϯ 0.69% (Fig. 6 , B and C). Easier signal integration was allowed by the addition of 10% (v/v) D 2 O in the buffer splitting the overlapping Na 2 S 2 O 3 signals. Thus, it was possible to obtain good estimations of IPM-Cl 2 , IPM-Cl/Alk, and IPM-Alk 2 abundances as a function of time, and hence estimations of k exp1 and k exp2 . These rate constants values are in close agreement with those described previously (Springer et al., 1998) .
Discussion
From metabolic investigations, the major finding was that dimethylated analogs were metabolized in the same way as IFO. However, three modifications in this metabolic pathway are to be noted. First, the metabolism rates of C7,C9-diMe-IFO were systematically higher than those of IFOs irrespective of the human or rat drug-induced microsomes used (approximately 50% with phenobarbital and 30% with Polychlorinated biphenyl). Second, with rat microsomes, TS125 metabolism mainly generated N 2 -DCP-Me-IFO, whereas TS121 produced higher rate of N 3 -DCP-Me-IFO. The opposite case was found when human microsomes were used. These results confirm the hypothesis that steric hindrance can modify metabolic regioselectivity. Finally, 4-hydroxylation rates for TS125 and IFO seemed very similar, whereas jpet.aspetjournals.org TS121 exhibited a higher rate of 4-hydroxylation using Polychlorinated biphenyl-induced rat microsomes. This may explain the higher cytotoxic activity and the higher alkylating reactivity found with this enantiomer (see below). A 4-hydroxylated metabolite was detected with both IFO analogs, tracing the formation of the nitrogen mustard, but the nonproductive side-chain oxidation products were also observed in important amounts for both analogs. However, CAA is not produced with these compounds because N-deschloroalkylation should lead to chloroacetone. This ketone is known to be toxic for external exposures at high concentrations. It is chemically less reactive than an aldehyde, as is CAA. Unfortunately, this labile ketone could not have been observed using ESI-mass spectrometry.
Oxazaphosphorines are activated by a 4-hydroxylation reaction catalyzed essentially by human P450 CYP2B6 and rat P450 CYP2B1 enzymes (Clarke and Waxman, 1989; Chang et al., 1993) . Because phenobarbital is a strong inducer of these later isoforms (Waxman et al., 1990) , and because the 9L-microsome coculture system has been described previously with phenobarbital-induced microsomes (Baldwin et al., 2003) , we choose this system to evaluate the cytotoxic activity of these IFO analogs with noninduced and phenobarbital-induced microsomes. As with IFO and CPM, phenobarbital-induced liver microsomes metabolize these two dimethylated IFO analogs to a greater extent than noninduced rat liver microsomes, leading to higher cytotoxic values. This difference is low for IFO, whereas the differences for dimethylated analogs and for CPM are comparable. These results are consistent with the higher catalytic activity of phenobarbital-inducible CYP2B1 described by Baldwin et al. (2003) with CPM, which is more efficiently activated than IFO.
Two differences have been noticed comparing alkylation kinetics of IPM and diMe-IPM. First, in the presence of trapping agents, both values of k exp1 and k exp2 are considerably higher for diMe-IPM than for IPM. Second, for the dimethyl mustard, k exp1 is approximately twice k exp2 , as for the alkylation reactions of isophosphoramide mustard. The diMe-IPM alkylates approximately 28 times faster than IPM and follows the same mechanism. Of course, the alkylation activity may be different with nucleotides or DNA, but the large differences between the two mustard alkylation rates clearly demonstrate that the diMe-IPM mustards are much more reactive through nucleophiles. This faster alkylation may be explained by the donor effect of the methyl group or by a modification of the three-dimensional conformation of the chloroethyl chains due to its steric hindrance. Thus, methyl aziridines should be stabilized and their formation facilitated.
The very rapid alkylation rate might jeopardize the ability of diMe-IPM to reach DNA tumor cells to cross-link them.
DiMe-IPM may also be deactivated by nucleophilic trapping agents. To answer this question, we plan to evaluate the activities of oxazaphosphorine analogs on mice xenografted with a panel of solid human tumors.
In the present work, new ifosfamide analogs with methylated side chains have been evaluated. The metabolism experiments with rat liver microsomes showed that metabolism rates were much higher for C7,C9-diMe-IFO analogs than for IFO. These investigations demonstrated that ring oxidation 
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at ASPET Journals on July 31, 2017 jpet.aspetjournals.org was enhanced especially with TS121, in the case of the Polychlorinated biphenyl microsomes. But the increase in nonproductive side-chain oxidation is many times greater. As the alkylating moiety was modified, the bisalkylating potential of these active compounds was studied with 31 P NMR experiments, showing that the diMe-IPM was a 28 times faster alkylating agent than IPM. These results have to be correlated with 6-fold higher cytotoxicity found during the 9L-microsomes cytotoxicity tests. The tested analogs are metabolized into more reactive mustards than IPM produced following IFO metabolism. Considering the cytotoxic activity, the cocultured microsome cell assays demonstrated that the cytotoxic activities of C7,C9-diMe-IFO analogs were greater than IFO and CPM, in agreement with the alkylating activity assay and the metabolic investigations. One of these analogs will be evaluated on mice xenografted with a panel of human solid tumors in the near future.
Side-chain oxidation still occurred, probably leading to chloroacetone after N-deschloropropylation. Although chloroacetone should be less toxic than chloroacetaldehyde and because very little is known about its effects on kidneys and nervous system (Sargent et al., 1986) , toxicities of chloroacetone and its analogs will be investigated in a rat renal model. 
